To determine the clinical profile and efficacy of accelerated recombinant tissue-type plasminogen activator (rt-PA) dose regimens, five different strategies of thrombolytic therapy in a total of 232 patients were systematically evaluated in the setting of acute myocardial infarction. The fifth strategy involved a combination of accelerated rt-PA and intravenous urokinase (regimen E). A weight-adjusted dose of 1.25 mglkg body weight of tissue plasminogen activator over 90 min (regimen C) yielded the highest coronary patency rate (83%) at acute angiography. The associated in-hospital reocclusion rate for this regimen was low (4%). An exaggerated (60-min) dosage regimen yielded an inferior coronary patency rate (63%). Combination therapy (regimen E) was associated with a 72% patency rate and 3% reocclusion rate.
To determine the clinical profile and efficacy of accelerated recombinant tissue-type plasminogen activator (rt-PA) dose regimens, five different strategies of thrombolytic therapy in a total of 232 patients were systematically evaluated in the setting of acute myocardial infarction. The fifth strategy involved a combination of accelerated rt-PA and intravenous urokinase (regimen E). A weight-adjusted dose of 1.25 mglkg body weight of tissue plasminogen activator over 90 min (regimen C) yielded the highest coronary patency rate (83%) at acute angiography. The associated in-hospital reocclusion rate for this regimen was low (4%). An exaggerated (60-min) dosage regimen yielded an inferior coronary patency rate (63%). Combination therapy (regimen E) was associated with a 72% patency rate and 3% reocclusion rate.
Marginal improvement in global ejection fraction and regional wall function was demonstrated with all strategies by predischarge catheterization. Bleeding complications were most common at the periaccess site and were not different from those in previous experiences reported with conventional 3-h dosing regimens.
The major goal of myocardial reperfusion therapy is to restore coronary blood flow as quickly as possible in the highest number of patients. To date, most coronary angiographic studies (1-5) 60 to 90 min after intravenous throm-Measurements of baseline, 30-min and 3-h levels of tissue plasminogen activator, fibrinogen and fibrin(ogen) degradation products were obtained. At 3 h, fibrinogen levels of <1 glliter were demonstrated with combination therapy (regimen E) as well as with regimen C. Major clinical outcomes including death, reocclusion and reinfarction also showed a tendency to be less common with regimen C.
Therefore, although accelerated dose regimens of rt-PA do not reliably yield acute coronary patency rates >85%, an acute coronary patency rate of approximately 85% can be approached. However, exaggerated (60-min) accelerated therapy may be associated with inferior coronary patency rates compared with conventional regimens.
The profile of heightened velocity of reperfusion, low reocclusion rates and a bleeding complication frequency comparable with that with conventional thrombolytic regimens suggests that accelerated rt-PA therapy deserves more extensive investigation.
(J Am Coli CardioI1992; 19:482-9) bolytic therapy have demonstrated a patency success rate :5.75%. Furthermore, the time to achieve thrombolysis has averaged~45 min in patients with successful early therapy (6) . Recently, however, new accelerated dosing regimens with intravenous recombinant tissue-type plasminogen activator (rt-PA) have achieved coronary thrombolysis more rapidly in~85% of patients (7) (8) (9) (10) . Experimental studies (11) have indicated that clot lysis may be proportional to drug levels, leading to the supposition that achieving higher levels early in treatment could both speed the rate and enhance the likelihood of reperfusion. We undertook a new clinical trial to systematically examine whether these "front-loaded" regimens (12) of rt-PA could be further improved by exaggerating the accelerated aspect of dosing. trying weight-adjusted dosing or replicating the promising results of other alternative regimens. Conventional dosing with 100 mg over 3 h was not employed because of our previous extensive data base documenting expected patency rates. Our preliminary hypothesis was that of a 20-mg intravenous bolus injection of rt-PA, followed by a 30-min wait, with 80 mg subsequently administered intravenously over the next 2 h. Finally, regimen E consisted of combination therapy with 1mg/kg of intravenous rt-PA over 30 min given simultaneously with 1.5 million U of urokinase over 1 h. This strategy was similar to that used in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI)-5 Study (4), except that front-loaded rt-PA was employed. In regimens A to C, no more than a maximum of 120 mg of tissue rt-PA was used. In regimen D, a total of 100 mg was given and in regimen E, a maximal dose of 90 mg was given.
Cardiac catheterization. All patients underwent emergency cardiac catheterization, including coronary angiography and left ventriculography, and delayed catheterization 5 to 10 days after the administration of thrombolytic therapy. Infarct-related artery patency, the primary end point of the study, was evaluated~90 min after the initiation of thrombolytic therapy. The infarct-related artery was identified as patent if Thrombolysis in Myocardial Infarction (TIM!) grade 2 or 3 flow was present at the time of the fourth diagnostic injection. An infarct-related vessel with TIMI grade 0 or 1 flow was defined as occluded. Left ventriculography was performed at the time of immediate catheterization and at the time of delayed catheterization 5 to 10 days later in the standard right anterior oblique projection.
All cineangiograms were evaluated independently at the core angiographic laboratory at the University of Michigan. Qualitative analysis included TIMI perfusion grade (5) and visual percent stenosis of the infarct-related vessel. This analysis was performed by a cardiologist and technician who had no knowledge of patient outcome. Global left ventricular function was determined by the area-length method and expressed as global ejection fraction (13) . Regional wall motion of the infarct and noninfarct zones was quantitatively evaluated and expressed as standard deviations/chord by means of the centerline chord method (14) . Technically inadequate studies due to lack of adequate contrast or frequent ventricular extrasystoles were not included in the analysis.
rt-PA =recombinant tissue-type plasminogen activator. Table 1 . Dosing Regimens accelerated infusion of intravenous rt-PA would achieve an acute coronary patency rate >85%. In addition, we were interested in observing associated reocclusion rates with accelerated therapy because few data exist concerning this potential complication at the time of trial initiation (7).
Methods
Patient enrollment. The trial was conducted at six regional cardiac referral centers in collaboration with 21 community hospitals (see Appendix). The protocol was approved by the Institutional Review Board at all participating sites. Patients were identified and prospectively enrolled in the emergency room setting.
Inclusion criteria included: age > 18 and <76 years; ability to give informed consent for participation in the study; symptoms consistent with acute myocardial infarction of >30-min duration unresponsive to standard sublingual nitroglycerin therapy;~1-mV ST segment elevation in at least two of three inferior leads, two of six precordial leads, leads I and aVL; ST segment depression in precordial leads V1 through V4 consistent with posterior injury and onset of ischemic symptoms :56 h from the time of thrombolytic therapy administration.
Exclusion criteria included: history of any significant bleeding diathesis or known bleeding disorder; history of gastrointestinal or genitourinary bleeding within the preceding 4 weeks; history of any previous stroke or transient ischemic attack; major surgery or organ biopsy within the previous 14 days; uncontrolled hypertension defined by several measurements as diastolic blood pressure > 110 mm Hg or systolic blood pressure> 180 mm Hg after treatment for pain; other serious advanced illnesses likely to limit the life expectancy in the next several years; prolonged cardiopulmonary resuscitation (> 10 min duration) within the previous 2 weeks; severe trauma within the past 6 months that might predispose the patient to intracranial, intrathoracic, intraabdominal or retroperitoneal bleeding; psychologic or physical inability to participate; women of child-bearing potential; prior coronary artery bypass graft surgery and prior Q wave infarction in the same electrocardiographic distribution as the current infarction.
Thrombolytic regimens ( Table 1) . Five thrombolytic drug regimens (regimens A to E) were systematically evaluated. Regimen A, designed to administer a high dose of rt-PA in an accelerated manner, employed a dosage of 1 mg/kg over 30 min intravenously (10% as a bolus injection), followed by 0.25 mg/kg over the next 30 min. To evaluate the importance of a front-loaded regimen at the same total dosage, 1.25 mg/kg of intravenous rt-PA was infused continuously over 90 min in regimen B; the first 20 mg was given as an intravenous bolus injection. Regimen C, similar to the protocol of Neuhaus et al. (7) Center at the Duke Databank for Cardiovascular Disease. The data were verified independently by study monitors through review of the clinical records. The Data and Safety Monitoring Board met regularly during the study to review the clinical outcome of each patient. After approximately 25 patients were treated with each regimen, the board recommended treating additional patients with the ongoing regimen or proceeding to the next dosage regimen. Specifically, if the upper 95% confidence limit for acute coronary patency did not exceed 85%, as defined by our primary hypothesis, the next regimen was initiated. (Table 2 ). A total of 232 patients were enrolled in the study; 219 were included in the final analysis. Three patients received no thrombolytic therapy and nine were misdiagnosed as having acute myocardial infarction. Of these nine, two had acute pericarditis, six had coronary artery disease but normal cardiac enzyme levels and one had normal coronary arteries by catheterization and did not "rule in" by enzyme analysis. One additional patient was inadvertently treated with a thrombolytic regimen different from that specified by the protocol.
The number of patients treated in each group and their baseline clinical and angiographic characteristics are listed in Table 2 . There were no substantial differences in baseline characteristics.
Patency and reocclusion rates (Table 3) . Infarct-related artery patency, the number of patients treated in each In-hospital care. After emergency catheterization, patients were transferred to the coronary care unit where they received standard care, including lidocaine, oxygen, morphine as needed for pain and nitrates either topically or intravenously. Aspirin (325 mg/day) was given immediately on entry into the study in the emergency room. Acontinuous infusion of intravenous heparin was also begun at 1,000 Ulh at the end of thrombolytic therapy administration. The patients continued to receive intravenous heparin until the time of repeat catheterization 5 to 10 days later and efforts were made to sustain the activated partial thromboplastin time at two times the control value for our laboratory. Intravenous beta-adrenergic blockade was used with metoprolol (15 mg over three divided doses) unless the patient was hypotensive, in cardiogenic shock, had severe chronic obstructive pulmonary disease or had second or third degree atrioventricular block. Patients were also treated with a calcium channel antagonist at the discretion of the clinician; no other antiplatelet agents such as dipyridamole were used routinely.
Hemorrhagic measurements. Bleeding observed during the hospital stay was defined as follows: mild if it was of no clinical consequence, did not require transfusion or resulted in a total blood loss of <250 ml; moderate if 250 to 500 ml of observed blood loss was noted; severe if any of the following events occurred: >500 ml of blood loss necessitating a transfusion, intracranial bleeding, gastrointestinal or other external or internal bleeding causing hypotension and requiring emergency transfusion. The site of bleeding, baseline and nadir hematocrit as well as transfused units of packed red blood cells were recorded for all patients. However, transfusion was withheld in hemodynamically stable patients unless the hematocrit was documented as <22%. In the setting of hemodynamic instability unresponsive to crystalloid infusion and with clinical evidence of significant blood loss, transfusions were given.
Coagulation tests. Blood samples were collected on 0.01 molar citrate and 200 kIU/ml aprotinin at baseline, 30 min and 3 h after initiation of thrombolytic therapy and were immediately processed and kept frozen at -20°C until assayed at the coagulation laboratory. Fibrinogen was determined by a coagulation rate assay. Fibrin(ogen) degradation products were analyzed by the tanned red cell agglutination inhibition technique at the core hematology laboratory at the University of Vermont. These techniques have been previously described (15) .
Statistical methods. Continuous baseline and outcome variables were summarized using the median and interquartile range (25th and 75th percentiles) and discrete variables are expressed as percent; 95% confidence intervals are calculated for major clinical outcomes. Because of the exploratory nature of the study. no statistical comparisons were performed.
Case report forms were completed by the clinical research nurse coordinators and reviewed by the principal investigators before submission to the Data Coordinator *Angiogram at 2:90 min. CI = confidence interval; rt-PA = recombinant tissue plasminogen activator; TAMI = Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Regimens A to E are defined in Table 1. regimen and the respective confidence intervals are shown in Table 3 . Regimen C achieved a 90-min patency rate of 83%, which was the highest rate observed for all five dosage strategies. The lowest patency rate, 64%, occurred with regimen B.
The proportion of patients with angiographically documented reocclusion in the five treatment regimens is also shown in Table 3 . Regimens D and A demonstrated the highest rate of reocclusion at 14% and 11%, respectively; the other regimens had a low reocclusion rate of 3% to 4%.
Baseline and follow-up left ventricular function (Table 4) . Although regimens A and E were associated with the most improvement in both global and regional wall function, predischarge left ventricular function was not significantly different for any of the five treatments.
Bleeding complications ( Table 5 ). The median change in hematocrit was not different among the five treatment groups. Although most bleeding complications involved the periaccess site, no clinically significant difference in moderate to severe bleeding was demonstrated among the different regimens. No intracranial bleeding episodes were noted in regimens A to D. However, with regimen E, there were two intracranial bleeding events. The first patient who experi- enced an intracranial bleeding episode had a history of hypertension for 15 years and remained hypertensive despite treatment with vasodilators. He developed receptive aphasia and total right-sided hemiparesis. The second patient with an intracranial bleeding event had a history of both hypertension and heavy alcohol consumption. He developed a left thalamic hemorrhage and, despite placement of a ventriculostomy tube, his neurologic status continued to deteriorate and he died 6 days after presentation.
Hematologic findings (Table 6 ). Baseline, 30-min and 3-h postinfusion levels for rt-PA, fibrinogen and fibrin(ogen) degradation products are shown in Table 6 . As expected, rt-PA levels were the highest in regimens A and E 30 min after starting the infusion. Levels were much lower at both 30 min and 3 h in regimen D, consistent with the delay between the bolus injection and subsequent infusion. Fibrinogen levels at 3h were considerably lower in regimens C and E than with the other strategies. Combination therapy with urokinase in regimen E was associated with a much higher level of fibrin(ogen) degradation products. Table I . Regimens A to E are defined in Table I .
Major clinical outcomes with the dift'erent drug regimens (Table 7) . Death, reocclusion, restenosis and reinfarction tended to be less frequent in regimen C. There was no significant difference in the incidence of recurrent ischemia or congestive heart failure among the different treatment strategies.
Discussion
This study demonstrates some of the limitations and potential advantages of accelerated rt-PA. First, accelerated weight-adjusted dose regimens were not associated with acute coronary patency rates >85%. In fact, a more accelerated dosage strategy over 60 min yielded the lowest patency rate of any regimen in the study. Despite rapid dosing and high early patency rates, the reocclusion rate of the infarct-related artery was not increased compared with previous studies of 3-h regimens. Finally, bleeding complications appear to be similar to those in previous reports with conventional infusion.
Patency rates. Regimens A, Band D produced early patency rates at immediate catheterization that were not Table 7 . Major Clinical Outcomes compatible with the potential for >85% patency as demonstrated by the 95% confidence intervals. For regimen A, the limited patency rate may have been a consequence of accelerated clearance of the drug with the exaggerated 60-min front-loaded infusion (16) . Regimen B, which yielded the lowest observed patency rate, perhaps emphasizes the need for the 30-min front-loaded infusion to improve the velocity and hence the effectiveness of accelerated administration. The patency rate in regimen D of only 67% is substantially lower than that previously reported (8) . This discrepancy may be due to sampling error because only 46 patients were evaluated. In addition, our final diagnostic injection at immediate catheterization occurred at a median time of 148 min and not 90 min. A high early patency rate followed by early reocclusion would not have been detected by these angiograms. Regimen C, a weight-adjusted regimen similar to that evaluated by Neuhaus et al. (7), yielded our best observed patency rate of 83%. Although the upper confidence limit for this particular strategy reached 93%, the interval for this point estimate was somewhat wide at 74% to 93%. Finally, with combination front-loaded rt-PA and urokinase in regimen E, a 72% patency rate was demon-
Death II  6  2  7  14  Reocclusion  II  3  4  14  3  Restenosis  5  9  0  2  0  Recurrent ischemia  35  18  30  20  17  Reinfarction  8  6  3  2  5  Congestive heart failure  24  27  30  35  26  Total stroke  3  3  0  2  5 Regimens A to E are defined in Table I . Regimen C is defined in Table 1. strated, which is similar to that reported with previous combination dosage schemes (2, 4, 17) .
The 83% patency rate achieved in regimen C fell short of the initial report of 90-min patency with accelerated therapy (7) . Even though our dose was weight-adjusted, the total amount of rt-PA administered over time was similar. However, our patency rate was almost identical to that observed by Carney et a1. (9) using the protocol of Neuhaus et a1. (7). This study reported a 90-min angiographically documented patency rate of 82% in 143 patients. In the recently completed Tissue Plasminogen Activator versus Anistreplase Patency Study (10) , the same accelerated regimen yielded an 84.6% 90-min patency rate in 195 patients. The patency rate with this front-loaded strategy was higher than that achieved with 30 U of anistreplase and was associated with a lower 28-day mortality rate. A heightened velocity of coronary patency was also demonstrated in all three studies (7, 9, 10) as documented by 60-min angiography when compared with conventional regimens (Table 8 ). The 6O-min patency rate of 74% to 76% compares favorably with the 45% to 60% patency rate observed with conventional regimens (6).
Reocclusion rates, There was concern that any regimen with a higher early patency rate might be associated with a greater propensity for reocclusion (18) . However, a surprising finding with rt-PA regimens is th~low reocclusion rate. The reocclusion rate of 4% with regimen C is much lower than the 13% rate seen in our previous studies (1-3,19) evaluating rt-PA as monotherapy. This finding is considerably lower than the 11% rate of reocclusion reported by Neuhaus et a1. (7) as well as others (10) and compares favorably with that reported with urokinase monotherapy (6%) (20) . The low reocclusion rate of 3% with combination therapy in regimen E is similar to previously reported rates from our study group (2, 4) . Although reocclusion of the infarct-related vessel has been reported (21, 22) as being exceptionally low with prolonged maintenance infusions of rt·PA, the same has not held true for the conventional 3-h regimen (6, 23) .
Ventricular function. Global ejection fraction and regional wall function showed a marginal improvement with all treatment strategies. Although the improvement from baseline to predischarge left ventricular function was greatest for regimens A and E, this finding most likely reflects worse baseline left ventricular function at the time of acute catheterization. Previous studies (24, 25) have shown that the most important predictor of improved systolic function is depressed baseline function. These findings are comparable to those in studies evaluating conventional dosing.
Bleeding complications. Overall, bleeding complications were not substantially different from those previously reported (1-6,23,26-28) in patients treated with conventional regimens of rt·PA. Most significant bleeding episodes occurred at the periaccess site. There were, however, two intracranial bleeding events in regimen E with combination therapy. Both patients had a predisposition for this complication. Furthermore, the incidence of intracranial bleeding in previous studies evaluating combination therapy has been low (4, 17) . Thus far, studies (7,9,10) evaluating front-loaded rt-PA monotherapy have been associated with a low (0.3%) intracranial bleeding rate, which is similar to or lower than the rate with conventional 3-h infusions.
Plasminogen activator and fibrinogen levels. This study demonstrates that high levels of rt-PA can be achieved within 30 min with accelerated therapy. The profound decrease in rt-PA levels by 3 h further emphasizes its short half-life and rapid clearance from the bloodstream. This finding perhaps reinforces the need for adequate anticoagulation once a fibrin-specific agent is administered to prevent reocclusion (29) (30) (31) .
A significant decrease in fibrinogen levels to <1 g/liter was seen in regimens C and E, representing a more profound decrease than that documented by previous studies (27, 28, 32, 33) . This may reflect less relative fibrin selectivity at high systemic drug levels. In addition, these two strategies produced a more sustained systemic fibrinolytic effect with higher levels of fibrin(ogen) degradation products documented at 3 h of infusion. As demonstrated with previous combination therapies (2, 4, 17) , the most profound increase was in regimen E with the addition of urokinase. Overall, these hematologic variables demonstrate that a substantial fibrinogenolytic effect can be achieved with front-loaded therapy. This perhaps correlates with the low reocclusion rate seen particularly in regimens C and E.
Clinical outcome. Although the number of patients treated in each group was small, the trend toward a more favorable clinical outcome in regimen C is of interest. The lower rate of death, reocclusion, reinfarction and intracranial bleeding is encouraging. However, recurrent ischemia as demonstrated with conventional rt-PA therapy remains a significant limitation of reperfusion therapy. This finding further emphasizes the need for the development of adjunctive therapies with fibrinolytic therapy to decrease the incidence of this adverse clinical outcome (19, 34) .
Limitations. Limitations of this study should be noted. The first is that this pilot study was open labeled and not randomized. Therefore, significant bias could exist in base-line characteristics among the groups. However, previous studies have not identified major clinical factors that have an impact on the likelihood of reperfusion. Second, confidence intervals for patency and reocclusion rates for each drug strategy were wide because of the small sample size.
Conclusions. Accelerated dose regimens of intravenous rt-PA do not reliably yield early (90-min) coronary patency rates >85%. However, an early coronary patency rate of approximately 85% can be approached. An accelerated rt-PA dose regimen, in which the drug is given too rapidly or without a significant front-loaded 30-min infusion, may be associated with lower coronary patency rates, probably reflecting saturation of plasminogen receptors (34) . Inhospital reocclusion rates appear to be low compared with those seen with conventional therapy. To date, bleeding complications are comparable to those previously reported. These findings suggest that further study is warranted to determine whether the heightened velocity and ceiling of this reperfusion method are associated with a better clinical outcome. Aweight-adjusted front-loaded regimen ofrt-PA is currently being investigated in an ongoing large international multicenter trial.
We sincerely appreciate the technical assistance of Cynthia Gardner in the preparation of the manuscript.
